Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Cabozantinib/Vandetanib

Lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Ciampi R, et al. NF1 gene inactivation acts as a tumor driver in RET/RAS-negative medullary thyroid carcinomas. European Journal of Endocrinology 188 : 430-437, No. 5, May 2023. Available from: URL: 10.1093/ejendo/lvad051 Ciampi R, et al. NF1 gene inactivation acts as a tumor driver in RET/RAS-negative medullary thyroid carcinomas. European Journal of Endocrinology 188 : 430-437, No. 5, May 2023. Available from: URL: 10.1093/ejendo/lvad051
Metadaten
Titel
Cabozantinib/Vandetanib
Lack of efficacy
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-58657-y

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Camrelizumab